JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A1196 SGX-523
1 Citation

Target: MET

Summary: MET inibitor, highly selective, ATP-competitive

≥17.95 mg/mL
A8393 CH5424802

Target: ALK

Summary: ALK inhibitor,potent and ATP-competitive
B2173 CP-673451

Target: PDGFR

Summary: PDGFRα/β inhibitor,potent and selective
B5854 Pexidartinib (PLX3397)
3 Citation

Target: FLT3|c-Kit|CSF1R

Summary: CSF-1R inhibitor

insoluble in EtOH; insoluble in H2O; ≥20.9 mg/mL
B1438 BMS-794833

Target: MET|Flk-1

Summary: Met/VEGFR-2 inhibitor,potent and ATP-competitive

≥23.45 mg/mL
A3020 (R)-Crizotinib
2 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL